Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 4/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.81 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833781 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17833785 | 0.91 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060469 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL731496 | 0.84 | PIK3CA (0.80) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17833776 | 0.84 | PIK3CA (0.89) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060445 | 0.84 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL730061 | 0.82 | PIK3CA (0.77) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060456 | 0.81 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060443 | 0.81 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17833784 | 0.81 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103788071-A | N-(5-(quinolyl-6-yl) pyridyl-3-yl)benzsulfamide derivatives, and preparation method and treatment use thereof | UNIV PLA 2ND MILITARY MEDICAL | 2014-05-14 | — | — | CN | claimed |
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SECOND MILITARY MEDICAL UNIVERSITY, PLA (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SECOND MILITARY MEDICAL UNIVERSITY, PLA (CN) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | GLS2, CYP3A5, HCCS | PIK3CA 532/4885MTOR 1636/4885PIK3CD 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.